The Booster lives! :)
Hey Niclou, don't know about three months, unless the resiliance of the SP over the past month or so counts. As Goethe said, coming events cast a shadow before them...
Or as Alan said...
"Normally at this kind of presentation I speak off-the-cuff, but because we are at a very exciting time for the company with many major developments that are very close to...are in process...I want to be very careful what I say so I'm going to use prepared comments because I think it will be safer for everybody."
"We have changed the rules of competition to such an extent that sometimes when we turn up to play there are no other competitors on the playing field.
"We are targetting many major therapeutic drug classes and more than 100 disease states including auto-immune, infectious disease and cancer.
"In short, we have unlimited opportunities to step up to the plate and hit a home run.
"That's why we can expect incremental growth as we add contract after contract after contract as we go forward from here today.
"There are also multiple levels from which we can now draw revenues. These include product development, customisation, selling devices for use in human clinical trials, long-term commercial supply contracts and exclusivity or royalty fees.
"After years of development we are now ready to serve as preferred partner to our pharmaceutical customers for delivery of their injectable drugs and vaccines.
"We expect to yield long-term operating margins north of 40% for Unifill.
"Please be on the look-out for news in this space relating to Unifill.
"Said one senior pharma executive upon seeing Ezimix - "For the first time ever I now know I am going to be able to commercialise one of the biologic drugs I am working with.
"Ezimix is now ready for commercialisation and we have received strong customer interest from a number of companies. Target gross margins for Ezimix will be around 60%.
"We are right on track to deliver these commercial Supply Agreeements. We are in late-stage discussions with many potential partners and expect to be announcing agreements shortly.
"We are actively discussing development agreements for our full range of products and injectable drug delivery systems with many pharmaceutical companies.
"These systems are ready to go for commercial development or for customisation.
"So in closing, this is a very exciting time for Unilife. In a relatively short time we have up-ended the entire drug delivery device market. Most importantly is the timing of our emergence in this market. The biologic drugs being developed today are game-changers for the pharmaceutical companies and also for the patients.
"Unilife is the first mover in the market to understand and accept the unique requirments of these drugs and we are ready to deliver."
Great presentation. It's all in there. Time is getting short!
Add to My Watchlist
What is My Watchlist?